On September 10, 2020 ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer reported the Company will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 and at the Cantor Fitzgerald Global Healthcare Conference 2020 on Thursday September 17, 2020 (Press release, ESSA, SEP 10, 2020, View Source [SID1234564981]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. David. R. Parkinson, Chief Executive Officer, will present a corporate overview of the Company’s business and participate in a fireside chat at the respective conferences. Dr. Parkinson along with ESSA’s Chief Operating Officer, Peter Virsik, and Chief Financial Officer, David S. Wood will be available for one-on-one meetings.

The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com. A replay of the presentations will be available on the Company’s website for 90 days.

H.C. Wainwright 22nd Annual Global Investment Conference

Presentation Date: Wednesday September 16, 2020
Presentation Time: 9:00am Pacific / 12:00pm Eastern

Cantor Fitzgerald Global Healthcare Conference 2020:

Fireside Chat Date: Thursday September 17, 2020
Fireside Chat Time: 11:40am Pacific / 2:40pm Eastern